Monitoring Recommendations
Recommendations for patient monitoring for the development of dyslipidemia, weight gain, and DM have been published.[6]They consider the potential metabolic risks when initiating an SGA; patient, family, and caregiver education; baseline screening; and referral to a specialist, if needed, as key components of patient care.[6] As weight gain is considered a precipitating factor for the development of DM and dyslipidemia, monitoring of weight changes with treatment is an important screening measure.